DOCSLIB.ORG

Adenosine Diphosphate Adenosine Monophosphate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adenosine Diphosphate Adenosine Monophosphate Volume 178, Supplement FEBS LETTERS December 1984 Cyclic AMP and the synthesis of phosphoenolpyruvate car- A boxykinase (GTP) mRNA Meisner H, Lamers W H & Hanson R W 1983 Trends Bio- them. Sci. 8, 165-167 Cyclic AMP, calcium and control of cell growth [Review Let- ter] ADENOSINE DIPHOSPHATE Ralph R K 1983 FEBS Lett. 161, 1-8 Purine nucleoside 3’,5’-cyclic monophosphates as hormonal Poly ADP-ribosylation of protein modulators of cellular proliferation, metastases and lympho- Pekala P H & Moss J 1983 Curr. Top. Cell. Regul. 22, 1 cyte response Robins R K 1982 Nucleosides Nucleotides, I, 205 Choleragen, adenylate cyclase, and ADP-ribosylation Vaughn M 1983 Harvey Lect. 77,43 Forskohn, cyclic AMP and cellular physiology Seamon K B & Daly J W 1983 Trends Pharmacol. Sci. 4, 120 Role of cyclic AMP in bacteria ADENOSINE MONOPHOSPHATE Ullmann A & Danchin A 1983 Advan. Cyclic Nucleotide Res. IS. 1 The egress of cyclic AMP from metazoan cells Role of cytoskeletal organization in the regulation of adenyl- Barber R & Butcher R W 1983 Advan. Cyclic Nucleotide ate cyclasecyclic adenosine monophosphate by hormones Res. 15, 119 Zor U 1983 Endocr. Rev. 4, 1 Biological significance of cyclic adenosine 3’,5’-monophos- phate in mosses [Minireview] Bhatla S C & Chopra R N 1983 Physiol. Plant. 57,383 ADENOSINE TRIPHOSPHATE The role of cyclic AMP in cell proliferation - a critical assess- ment of the evidence Boynton A L & Whitfield J F 1983 Advan. Cyclic Nucleotide Role of ATP in the regulation of stability of cytoskeletal struc- Res. 15, 193 tures [Minireview] Bershadsky A D & Gelfand V I 1983 Cell Biol. Int. Rep. 7, Cyclic AMP in photosynthetic organisms - recent develop- 173 ments Francko D A 1983 Advan. Cyclic Nucleotide Res. 15.97 Localization of alkaline phosphatase and adenosine triphos- phatase in the mammalian pancreas Vasopressm isoreceptors in mammals - relation to cyclic Githens S 1983 J. Histochem. Cytochem. 31,697 AMP-dependent and cyclic AMP-independent transduction mechanisms Mechanism of ATP synthesis and coupled proton transport: Jard S 1983 Curr. Top. Membr. Transport, 18.255 studies with purified chloroplast coupling factor Hammes G G 1983 Trends Biochem. Sci. 8. 131-134 Cyclic adenosine monophosphate eystem and bacterial exotox- ins [In German; English abstract] Coupling of proton flux to the hydrolysis and synthesis of Kather H & Aktories K 1983 Khn. Wochenschr. 61, 1109 ATP Wang J H 1983 Annu. Rev. Biophys. Bioeng. 12,21 a,-Adrenoceptors beyond CAMP generation: islets of Langer- hans and intestinal epithelium Kato R & Nakaki T 1983 Trends Pharmacol. Sci. 4. 34 Cell cell contact, cyclic AMP and gene expression during de- velopment of Dictyostelium discoideum Mangiarotti G, Bozzaro S, Landfear S & Lodish H F 1983 Curr. Top. Dev. Biol. 18, 117 Volume 178, Supplement FEBS LETTERS December I984 ADIPOSE TISSUE Neuropharmacology of degenerative diseases associated with aging Growdon J H 1983 Med. Res. Rev. 3.221 Brown adipose tissue in man: a review Blaza S 1983 J. Roy. Sot. Med. 76,213 The biological aging process [Minireview] Hahn H P von 1983 E.rperientuz, 39,47 Adrenergic regulation of adipocyte metabolism Fain J N & Garcia-Sainz J A 1983 J. Lipid Res. 24, 945 Bioenergetics in aging Hansford R G 1983 Biochim. Biophys. Acta, 726,41 Luxuskonsumption, brown fat and human obesity Garrow J S 1983 Br. Med. J. 286, 1684 Development, maturation, and aging of synapses Jones D G 1983 Advan. Cell. Neurobiol. 4, 163 The insulin-sensitive hexose transport system in adipocytes Gliemann J & Rees W D 1983 Curr. Top. Membr. Truns- Conference on Biological Aspects of Alzheimer’s Disease, port, 18, 339 Cold Spring Harbor, NY, October 1982 Katzman R, ed. 1983 Banbury Rep. 15,495 pp. Brown adipose tissue thermogenesis in obese animals Himms-Hagen J 1983 Nutr. Rev. 41,261 Neuronal aging in tissue and cell cultures: a review Kim S U 1983 In Vitro, 19, 73 The regulation of fatty acid synthesis in brown adipose tissue by insulin Dementia of the Alzheimer type: a review of progress in re- McCormack J G 1983 Progr. Lipid Res. 21, 195 search Lamour Y & Davous P 1983 Presse Med. I2, 1415 The thermogenic mechanism of brown adipose tissue - re- view Does the female life span exceed that of the male? A study in Nicholls D G 1983 Biosci. Rep. 3,431&441 Drosophila melunoguster [Critical review] Lints F A, Bourgois M, Delalieux A, Stoll J & Lints C V 1983 Gerontology, 29, 336 Special Symposium: The Measurement of Biological Age AGEING Ludwig F C & others 1983 Exp. Aging Res. 9,219 Changes in membrane properties associated with cellular ag- Carcinogenesis and aging ing Anisimov V N 1983 Advan. Cancer Res. 40,365 Macieiracoelho A 1983 Int. Rev. Cytol. 83, 183 Sleep in normal and pathological aging Protein synthesis and degradation during aging and senescence Blots R, Feinberg I, Gaillard J-M, Kupfer D J & Webb Makrides S C 1983 Biol. Rev. 58, 343 W B 1983 Experientia. 39, 551 Endocrine functions in the elderly (70 years and over) The reticuloendothelial system and aging: a review Mineur Ph, Favre L, Burger A G & Vallotton M B 1983 Brouwer A & Knook D L 1983 Mech. Ageing Dev. 21,205 Schweiz. Med. Wochenschr. II3. 13 10 Assessing the noradrenergic system in normal aging: a review Nutrition and longevity of methodology Morrison S D 1983 Nutr. Rev. 41, 133 Cutler N R & Hodes J E 1983 Exp. Ageing Res. 9, 123 Drug metabohsm in the elderly - confounding of age, smok- The neurochemistry of Alzheimer’s disease and senile demen- ing and ethanol effects tia Sellers E M, Frecker R C & Romach M K 1983 Drug Me- Davies P 1983 Med. Res. Rev. 3, 221 tab. Rev. 14, 225 The ageing muscle [Minireview] The histochemistry of ageing Grimby G & Saltin B 1983 Clin. Physiol. 3, 209 Wilson P D 1983 Histochem. J. IS, 393 2 Volume 178, Supplement FEBS LETTERS December 1984 ALCOHOL ALGAE Effects of ethanol on the male hypothalamic-pituitary-go- Light-harvesting processes in algae nadal axis Larkum A W D & Barrett J 1983 Advan. Bot. Res. IO, 1 Boyden T W & Pamenter R W 1983 Endocr. Rev. 4,389 Botryococcus braunii. An unusual hydrocarbon-producing Symposium: Alcohol and Endocrine Systems Interaction - alga Part II Wolf F R 1983 Appl. Biochem. Biotechnol. 8,249 Chiao Y-B&others 1983 Alcoholism, 7, 131 Metabolic acidosis in the alcoholic: a ~thophysio~o~c ap- proach Halperin M L, Hammeke M, Josse R G & Jungas R L 1983 ALKALOIDS Metabolism, 32, 308 The effect of ethanol on GABAergic transmission Structure and synthesis of benzoquinolizidine alkaloids isolat- Hunt W A 1983 Neurosci. Biobehav. Rev. 7,87 ed from Alangium lamarckii. [In Japanese; English abstract] Fujii T 1983 Yakugaku Zasshi, 103,257 Technology and economics of fermentation alcohol - an up- date Yohimbine: a pharmacological probe for the study of the as- Keim C R 1983 Enzyme h&rob. Technol. 5. 103 adrenoreceptor Goldberg M R & Robertson D 1983 Pharmacol. Rev. 3.5, Ethanol and GABA 143 Kulonen E 1983 Med. Biof. 61,147 Pyrrolizidine alkaloids, flavonoids and volatile compounds in Tolerance and physical dependence on alcohol at the level of the genus Euputorium. Eupaior~~ c~abin~ L., an ancient synaptic membranes: a review drug with new perspectives Littleton J M 1983 J. Roy. Sot. Med. 74, 593 Hendriks H, Malingre Th M & Elema E T 1983 Pharm. Weekbl. 5, 28 I Zinc deficiency in the alcoholic: a review McClain C J & Su L-C 1983 Alcoholism, 7, 5 Ceveratrum alkaloids: progress in understanding their mem- brane and inotropic actions The neurotoxicity of ethanol Honerjager P 1983 Trends Pharmacol. Sci. 4,258 Melgaard B 1983 Acra Neural. Stand. 67, 13 1 New developments in indole alkaloids First Congress of the International Society for Biomedical Re- Kuehne M E, ed. 1983 Tetrahedron, 39, Symposium-Print search on Alcoholism No. 12,3627 Michaelis E K & others 1983 Pharmacol. Bioehem. Behav. 18, Suppl. I, 1 The African Strychnos species and their alkaioids: a review Ohiri F C, Verpoorte R & Svendsen A B 1983 J. Ethnophar- Alcohol and y-glutamyltransferase [In English] macol. 9, 167 Nishimura M & Teschke R 1983 Klin. Wochenschr. 61,265 Bisbenzylisoquinoline alkaloids Prostaglandins in alcohol intolerance and hangover Schiff P L, jr 1983 J. Nat. Prod. (Lloydia), 46, 1 Parantainen J 1983 Drug Alcohol Depend. 1 I, 239 Muscarinic and g-adrenergic prejunctional modulation of ad- Concepts on the biotransformation of carbohydrates into fuel renergic neurotransmission in the blood vessel wail ethanol Vanhoutte P M C Shepherd J T 1983 Gen. Pharmacol. 14, Rob C & others 1983 Advan. Biotechnol. Processes, I, 97 35 Drug metabolism m the elderly - ~nfounding of age, smok- ing and ethanol effects Sellers E M, Frecker R C & Romach M K 1983 Drug Me- tab. Rev. 14, 225 3 Volume 178, Supplement FEBS LETTERS December I984 AMINES 5-HTz receptor blockade to study serotonm-induced patholo- Seealso: CATECHOLAMINES AND RECEPTORS gy Janssen P A J 1983 Trenlis Pharmacol. SCI. 4, 198 Lithium and central monoamine neurotransmitter systems Trace btogenic amines: a possible functtonal role in the CNS [Current Trends Review] Jones R S G 1983 Trends Pharmacol. SCI. 4,426 Ahluwaha P & Singhal R L 1983 Drug Dev. Res. 3, 111 Agents that release htstamine from mast cells 7th International Symposium on N-Nitroso Compounds, To- Lagunoff D, Martin T W & Read G 1983 Annu. Rev. Phar- kyo, Japan, September 28Octobcr 1, 198 1 macol. Toxtcol. 23,331-351 Bartsch H, O’Neill I K & Castegnaro M, eds 1982 IARC Sci. Publ. No. 41. 753 pp. Sir Thomas Lewis’s nocifensor system, histamine and sub- stance-p-containing primary afferent nerves Muscarinic receptor subclasses Lembeck F 1983 Trends Neurosci.
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers
    Japan. J. Pharmacol. 55, 359-366 (1991) 359 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers Hideki Ono, Hiroyuki Ito and Hideomi Fukuda' Departmentof Toxicologyand Pharmacology,Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo,Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan 'Departmentof Pharmacology, Collegeof Pharmacy,Nihon University, 7-7-1Narashinodai, Funabashi, Chiba 274, Japan ReceivedJuly 28, 1990 AcceptedDecember 27, 1990 ABSTRACT Experiments were performed on spinalized rats transected at C1. In travenous administration of 2-phenylethylamine-HC1 (PEA-HC1) (0.3 and 1 mg/kg, i.v.) and methamphetamine-HC1 (MAP-HC1) (0.1 and 0.3 mg/kg, i.v.) increased the amplitude of the monosynaptic reflex (MSR). The increase of the MSR caused by PEA and MAP was antagonized by prazosin-HC1 and abolished by the pretreatment with reserpine (i.p.) and 6-hydroxydopamine (intracisternally, 14 days previously). A dopamine D, antagonist, SK&F 83566-HBr (0.01 mg/kg, i.v. ), and a D2 antagonist, YM-09151-2 (0.3 mg/kg, i.v.), did not antagonize the increasing effects produced by PEA and MAP. An inhibitor of type-B monoamine oxidase, (-)deprenyl-HC1 (1 mg/kg, i.v.), prolonged the effect of PEA but not that of MAP, suggesting that PEA alone, and not its metabolites, enhanced the MSR. These results suggest that PEA and MAP increase the amplitude of the MSR by releasing noradrenaline from the ter minals of descending noradrenergic fibers, and that PEA, an endogenous trace amine, has a mechanism of action similar to that of MAP.
    [Show full text]
  • Tyramine and Amyloid Beta 42: a Toxic Synergy
    biomedicines Article Tyramine and Amyloid Beta 42: A Toxic Synergy Sudip Dhakal and Ian Macreadie * School of Science, RMIT University, Bundoora, VIC 3083, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-3-9925-6627 Received: 5 May 2020; Accepted: 27 May 2020; Published: 30 May 2020 Abstract: Implicated in various diseases including Parkinson’s disease, Huntington’s disease, migraines, schizophrenia and increased blood pressure, tyramine plays a crucial role as a neurotransmitter in the synaptic cleft by reducing serotonergic and dopaminergic signaling through a trace amine-associated receptor (TAAR1). There appear to be no studies investigating a connection of tyramine to Alzheimer’s disease. This study aimed to examine whether tyramine could be involved in AD pathology by using Saccharomyces cerevisiae expressing Aβ42. S. cerevisiae cells producing native Aβ42 were treated with different concentrations of tyramine, and the production of reactive oxygen species (ROS) was evaluated using flow cytometric cell analysis. There was dose-dependent ROS generation in wild-type yeast cells with tyramine. In yeast producing Aβ42, ROS levels generated were significantly higher than in controls, suggesting a synergistic toxicity of Aβ42 and tyramine. The addition of exogenous reduced glutathione (GSH) was found to rescue the cells with increased ROS, indicating depletion of intracellular GSH due to tyramine and Aβ42. Additionally, tyramine inhibited the respiratory growth of yeast cells producing GFP-Aβ42, while there was no growth inhibition when cells were producing GFP. Tyramine was also demonstrated to cause increased mitochondrial DNA damage, resulting in the formation of petite mutants that lack respiratory function.
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-Phenylethylamine Derivatives
    Physiol. Res. 51: S13-S19, 2002 The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-phenylethylamine Derivatives A. J. GREENSHAW1, S. TURKISH2, B. A. DAVIS2 1Neurochemical Research Unit, Department of Psychiatry, University of Alberta and 2Neuropsychiatric Research Unit, University of Saskatchewan, Canada Summary The functional aversive stimulus properties of several IP doses of (±)-amphetamine (1.25-10 mg.kg-1), 2-phenylethylamine (PEA, 2.5-10 mg.kg-1, following inhibition of monoamine oxidase with pargyline 50 mg.kg-1) and phenylethanolamine (6.25-50 mg.kg-1) were measured with the conditioned taste aversion (CTA) paradigm. A two-bottle choice procedure was used, water vs. 0.1 % saccharin with one conditioning trial and three retention trials. (±)-Amphetamine and phenylethanolamine induced a significant conditioned taste aversion but PEA did not. (±)-Amphetamine and PEA increased spontaneous locomotor activity but phenylethanolamine had no effects on this measure. Measurement of whole brain levels of these drugs revealed that the peak brain elevation of PEA occurred at approximately 10 min whereas the peak elevations of (±)-amphetamine and phenylethanolamine occurred at approximately 20 min. The present failure of PEA to elicit conditioned taste aversion learning is consistent with previous reports for this compound. The differential functional aversive stimulus effects of these three compounds are surprising since they exhibit similar discriminative stimulus properties and both (±)-amphetamine and PEA are self- administered by laboratory animals. The present data suggest that time to maximal brain concentrations following peripheral injection may be a determinant of the aversive stimulus properties of PEA derivatives. Key words 2-phenylethylamine • (±)-amphetamine • Phenylethanolamine • Conditioned taste aversion • Locomotor activity • Drug levels Introduction (Greenshaw et al.
    [Show full text]
  • The Role of Norepinephrine in the Pharmacology of 3,4
    !"#$%&'#$&($)&*#+,-#+"*,-#$,-$."#$/"0*102&'&34$&($ 56789#."4'#-#:,&;41#."01+"#.01,-#$<9=9>6$?#[email protected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`,E#-E$ I0--$ D-.#*$ 2*#0.,J#2&11&-@X&*3a',2#-2#@aY48-28 -:aSX]a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
    [Show full text]
  • Principles-Of-Autonomic-Medicine-V
    Principles of Autonomic Medicine v. 2.1 DISCLAIMERS This work was produced as an Official Duty Activity while the author was an employee of the United States Government. The text and original figures in this book are in the public domain and may be distributed or copied freely. Use of appropriate byline or credit is requested. For reproduction of copyrighted material, permission by the copyright holder is required. The views and opinions expressed here are those of the author and do not necessarily state or reflect those of the United States Government or any of its components. References in this book to specific commercial products, processes, services by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply their endorsement, recommendation, or favoring by the United States Government or its employees. The appearance of external hyperlinks is provided with the intent of meeting the mission of the National Institute of Neurological Disorders and Stroke. Such appearance does not constitute an endorsement by the United States Government or any of its employees of the linked web sites or of the information, products or services contained at those sites. Neither the United States Government nor any of its employees, including the author, exercise any editorial control over the information that may be found on these external sites. Permission was obtained from the following for reproduction of pictures in this book. Other reproduced pictures were from -- 1 -- Principles of Autonomic Medicine v. 2.1 Wikipedia Commons or had no copyright. Tootsie Roll Industries, LLC (Tootsie Roll Pop, p. 26) Dr. Paul Greengard (portrait photo, p.
    [Show full text]
  • Demonstration and Distribution of Phenylethanolamine in Brain And
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 3, pp. 769-772, March 1973 Demonstration and Distribution of Phenylethanolamine in Brain and Other Tissues (enzyme assay/intraneural synthesis and storage/phenylethylamine/phenylalanine/rat) JUAN M. SAAVEDRA AND JULIUS AXELROD Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014 Contributed by Julius Axelrod, December 26, 1972 ABSTRACT A specific and sensitive assay for phenyl- of a mixture containing 10 ul of partially purified phenyl- ethanolamine in tissues is described. By this assay, phenyl- ethanolamine was detected in many peripheral tissues and ethanolamine N-methyltransferase, 5 Ml (0.54 nmol) of brains of rats. It is unequally distributed in rat brain, with [3H]methyl-S-adenosyl-l-methionine (specific activity, 4.54 the highest concentration present in hypothalamus and Ci/mmol) and 35 ul of 20 mM Tris * HCl buffer (pH 8.6). 1 ng midbrain. Concentrations of brain phenylethanolamine of phenylethanolamine was added to another aliquot as an were elevated after administration of phenylethylamine, internal standard. The incubation was stopped by addition of phenylalanine, p-chlorophenylalanine, and monoamine oxidase inhibitors and decreased after administration of 0.5 ml of 0.5 M borate buffer (pH 10) and the radioactive dopamine-fl-hydroxylase inhibitors. Denervation of sym- product was extracted with 6 ml of a mixture containing 95% pathetic nerves caused a moderate fall in phenylethanol- heptane and 5% isoamyl alcohol (v/v), by shaking for 15 sec. amine concentrations. These results indicate that phenyl- After the phases were separated by centrifugation, a 5-ml ethanolamine is synthesized intraneuronally from phenyl- alanine and phenylethylamine, but that only part of the aliquot of the organic phase was transferred to counting vials phenylethanolamine is stored in sympathetic nerves.
    [Show full text]